Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSu...
Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)
- Conditions
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT05164250
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 317
- Registration Number
- NCT05137054
- Locations
- 🇺🇸
Dana Farber/Harvard Cancer Center, Boston, Massachusetts, United States
🇺🇸Scripps Clinic Torrey Pines, La Jolla, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
- Conditions
- Interventions
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 190
- Registration Number
- NCT05133531
- Locations
- 🇵🇪
Clinica San Felipe, Lima, Peru
🇵🇭St Lukes Medical Center, Quezon City, Central Luzon, Philippines
🇨🇳Taichung Veterans General Hospital (VGHTC), Taichung City, Taiwan
Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria
- Conditions
- Interventions
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 2
- Registration Number
- NCT05131204
- Locations
- 🇺🇸
Regeneron Research Facility, Whittier, California, United States
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-18
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 370
- Registration Number
- NCT05125016
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive A Kidney Transplant
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT05106387
- Locations
- 🇺🇸
New York University Langone Health - Transplant Institute, New York, New York, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9933 in Adult Healthy Volunteers
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT05102136
- Locations
- 🇧🇪
Regeneron Study Site, Edegem, Antwerp, Belgium
Study for Desensitization of Chronic Kidney Disease in Adult Patients in Need of a Kidney Transplant Who Are Highly Sensitized to Human Leukocyte Antigen
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT05092347
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸University of California, Irvine, Orange, California, United States
COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 2
- Registration Number
- NCT05092581
- Locations
- 🇺🇸
Le Bonheur Children's Hospital, Memphis, Tennessee, United States
🇺🇸State University of New York at Stony Brook, Stony Brook, New York, United States
A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)
- Conditions
- Interventions
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT05088460
- Locations
- 🇺🇸
National Institute of Health, Bethesda, Maryland, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸Excel Medical Clinical Trials - A Flourish Research Site, Boca Raton, Florida, United States